Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:50:48.155Z.
Calculation as of: 2026-10-06T18:50:48.155Z.
Quote observation: 2026-10-06T18:48:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e9e072c721023a8f5b36c3f5b81ac18026d6678c99aa2a087bce1e48ab153e53
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$4.72M
EV/Sales Ratio
0.50x
TTM Avg
5.83x
3Y Avg
31.22x
5Y Avg
31.22x
Market Cap
$4.59M
EV/Sales Ratio
N/A
TTM Avg
3707.31x
3Y Avg
3707.31x
5Y Avg
3707.31x
Market Cap
$5.06M
EV/Sales Ratio
N/A
TTM Avg
0.61x
3Y Avg
0.46x
5Y Avg
2.93x
Market Cap
$4.95M
EV/Sales Ratio
8.05x
TTM Avg
29.50x
3Y Avg
46.21x
5Y Avg
38.89x
Market Cap
$4.28M
EV/Sales Ratio
12.54x
TTM Avg
5.50x
3Y Avg
15.32x
5Y Avg
34.36x
Market Cap
$5.01M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CalciMedica, Inc. (CALC) | $4.63M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | 0.50x | 5.83x | 31.22x | 31.22x |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.59M | N/A | 3707.31x | 3707.31x | 3707.31x |
| Xenetic Biosciences, Inc. (XBIO)vs › | $5.06M | N/A | 0.61x | 0.46x | 2.93x |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.95M | 8.05x | 29.50x | 46.21x | 38.89x |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.28M | 12.54x | 5.50x | 15.32x | 34.36x |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.01M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.33M | 0.18x | 0.77x | 0.77x | 0.77x |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.07M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
